Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.70 USD
Change Today -0.22 / -2.47%
Volume 14.6K
EBIO On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 2:18 PM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

eleven biotherapeutics inc (EBIO) Snapshot

Open
$8.94
Previous Close
$8.92
Day High
$9.08
Day Low
$8.65
52 Week High
04/2/14 - $17.48
52 Week Low
04/1/15 - $8.65
Market Cap
157.5M
Average Volume 10 Days
104.0K
EPS TTM
$-2.46
Shares Outstanding
18.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ELEVEN BIOTHERAPEUTICS INC (EBIO)

Related News

No related news articles were found.

eleven biotherapeutics inc (EBIO) Related Businessweek News

No Related Businessweek News Found

eleven biotherapeutics inc (EBIO) Details

Eleven Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of protein therapeutics to treat eye diseases primarily in the United States. The company develops its therapeutics through AMP-Rx, a proprietary protein engineering platform. Its product candidates include EBI-005, a novel interleukin-1 receptor antagonist that is in Phase III clinical program for the treatment of moderate to severe dry eye diseases; and has completed Phase II clinical trial for the treatment of allergic conjunctivitis. The company’s preclinical product candidates comprise EBI-031, a novel inhibitor of the cytokine interleukin-6 for the treatment of retinal diseases, such as diabetic macular edema; and EBI-028, a novel inhibitor of the cytokine interleukin-17 for the treatment of uveitis, and other diseases of the back of the eye, such as dry age-related macular degeneration. Eleven Biotherapeutics, Inc. has a collaboration and license agreement with ThromboGenics N.V. to identify protein or peptide therapeutics that directly modulate any of a specified set of targets in a novel pathway in retinal disease. The company was founded in 2008 and is based in Cambridge, Massachusetts.

21 Employees
Last Reported Date: 03/6/15
Founded in 2008

eleven biotherapeutics inc (EBIO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $570.9K
Chief Financial and Business Officer
Total Annual Compensation: $429.9K
Chief Development Officer
Total Annual Compensation: $198.0K
Chief Scientific Officer
Total Annual Compensation: $402.4K
Compensation as of Fiscal Year 2014.

eleven biotherapeutics inc (EBIO) Key Developments

Eleven Biotherapeutics Seeks Acquisitions

Eleven Biotherapeutics, Inc. (NasdaqGM:EBIO) has filed a Shelf Registration in the amount of $200.00 million, Eleven Biotherapeutics will use the net proceeds for research and development of our product pipeline, acquisition of companies or businesses, repayment and refinancing of debt, working capital and capital expenditures.

Eleven Biotherapeutics, Inc. Reports Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Eleven Biotherapeutics, Inc. reported unaudited earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported collaboration revenue of $375,000 compared to $510,000 a year ago. Loss from operations was $7,095,000 compared to $4,120,000 a year ago. Net loss applicable to common stockholders was $8,139,000 or $0.49 per basic and diluted share compared to $6,208,000 or $4.29 per basic and diluted share a year ago. For the year, the company reported collaboration revenue of $2,243,000 compared to $1,334,000 a year ago. Loss from operations was $32,931,000 compared to $16,478,000 a year ago. Net loss applicable to common stockholders was $34,675,000 or $2.37 per basic and diluted share compared to $21,882,000 or $16.18 per basic and diluted share a year ago.

Eleven Biotherapeutics, Inc. to Report Q4, 2014 Results on Mar 04, 2015

Eleven Biotherapeutics, Inc. announced that they will report Q4, 2014 results at 8:30 AM, US Eastern Standard Time on Mar 04, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EBIO:US $8.70 USD -0.22

EBIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EBIO.
View Industry Companies
 

Industry Analysis

EBIO

Industry Average

Valuation EBIO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 68.8x
Price/Book 4.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 46.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELEVEN BIOTHERAPEUTICS INC, please visit www.elevenbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.